Lederle beta blocker license
Executive Summary
Lederle will market bisoprolol, a "third generation cardioselective" beta blocker developed by E. Merck (Germany), in the U.S. and Canada. The once-a-day product, licensed through E. Merck's U.S. affiliate E.M. Industries, is approved in West Germany where a launch is planned for this spring, with marketing in other European countries to follow within two years, Lederle said. Lederle will handle NDA filing based on U.S. clinical data from ongoing studies sponsored by E.M. Industries.